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Abstract
 Background—The enhanced sensitivity of cardiac troponin T (cTnT) assays calls for its use 
as a prognostic marker in chronic heart failure, as an accurate and early marker of myocyte 
damage, and as a sensitive indicator of acute episodes in chronic disease. To facilitate these 
applications and inform required benchmarks, we estimated the variability in cTnT measurements, 
the sources of this variability, and the stability of cTnT using samples stored at −70 °C.
 Methods and Results—Stored samples from the Atherosclerosis Risk in Communities 
Study (ARIC) study (1996–1998) and ARIC Carotid MRI study participants (2005–06) were 
assayed in 2009–10 to examine variability in cTnT attributable to laboratory (replicates after 
freeze thaw, n=29), processing (blind replicates from same blood draw, n = 87), short- (n = 40) and 
long-term biological variation (repeat visit, n = 38), and degradation in frozen storage (n = 
10,870). The Elecsys Troponin T (Roche Diagnostics, Indianapolis, IN) was used to assay cTnT 
on an automated Cobas e411 analyzer. The lower limit of detection was 3 ng/L. Approximately 
1/4th to 1/3rd of the participants had values below the detection limit. The paired correlation for all 
other comparisons exceeded 0.93 (except for samples drawn 8 years apart = 0.36). The coefficients 
of variation for individual sources of variation in cTnT were as follows: laboratory 2.1% in those 
with heart failure (HF) and 11.2% in those without HF; processing 18.3%; biological at six weeks 
16.6%, and at eight years 48.4%. The reference change value at 6 weeks was 68.5% and would 
require 4 samples to determine homeostatic set point within ± 25%. Only modest degradation was 
detected in stored frozen samples for an average of 8 years.
 Conclusions—cTnT is detectable in approximately 70% of community-dwelling men and 
women aged 53 to 75 years. The laboratory reliability was high: the reliability coefficient (r) was 
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0.99 in those with heart failure and 0.94 in those without heart failure. The intra-individual 
(biologic) variability was low on repeat testing after 6 weeks (r=0.94), and increased for 
measurements taken 8 years apart (R=0.36). Troponin T is stable in storage at −70° C and the 
variability in cTnT values attributable to one freeze-thaw cycle is of small magnitude.
Keywords
highly sensitive Troponin T; hsTnT; cTnT; variability; measurement error; laboratory variability; 
intra-individual variation
 Introduction
Cardiac troponins are markers of myocardial injury commonly used in the diagnosis of acute 
coronary events [1–4]. Increased concentrations of circulating troponins are also detectable 
in patients with both acute decompensated and chronic heart failure (HF) and have been 
associated with poor patient outcomes [5–12]. Troponin concentrations are generally lower 
in chronic HF patients than those seen in acute coronary syndromes [13], and therefore 
necessitate sensitive troponin assays. For example, the highly sensitivity cardiac troponin T 
(cTnT) assay can detect troponin T concentrations more than 10-fold lower than with 
traditional assays [14]
There is limited information on the variability of cTnT in individuals not examined in an 
acute care context, although a 1999 report from the National Academy of Clinical 
Biochemistry Standards of Laboratory Practice emphasized a need for such studies [15]. 
Such information is important to determine cutoffs to suggest an acute event in individuals 
with chronic troponin T elevation. The variability of cTnT was recently reported to be higher 
than that of the commonly used Troponin I [16].
We examined the variability of cTnT in Atherosclerosis Risk in Communities (ARIC) 
participants and quantified the components of variability attributed to laboratory, processing, 
and biological variation. We also estimated the impact of specimen storage at −70 degrees 
Celsius over three years on levels of cTnT.
 Methods
 Study Sample
The ARIC Study cohort of middle aged African American and Caucasian males and females 
was enrolled in 1987–89, sampled from four US communities. The baseline examination 
(1987–89) was followed by three triennial field center visits. Subsequently, novel cellular, 
metabolic and genomic correlates of carotid atherosclerosis and early pathologic changes in 
the carotid artery walls were measured in 2,066 cohort members by the ARIC Carotid MRI 
Study (2005–06). The present study assayed stored samples from the visit 4 (1996–98) to 
study stability of cTnT over three years of sample collection. To study the components of 
variability, stored samples from Carotid MRI study were used. The study was approved by 
the institutional review boards of the four participating centers.
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 Blood Sampling and Processing
Participants were requested to report after an overnight fast. Venipuncture and specimen 
processing were performed by centrally trained technicians, using standard protocols at the 
four field centers. The samples from visit 4 were stored at the field center in a sytrofoam 
boxes in freezer at −70 ° C, and were shipped every Monday to the central lab by overnight 
courier. The samples from Car MRI study were shipped on the day of blood draw in 
insulated styrofoam containers with temperature-stabilizing packages (approximate 
specimen temperature 10–15 °C) by overnight courier to the ARIC central laboratory [17], 
and stored at −70 ° C until assayed for this study. The stored samples were assayed in 2009–
10.
 Biomarker Assays
Plasma samples were stored centrally at –70°C and used for measurement of the biomarkers. 
cTnT levels were measured with a novel pre-commercial highly sensitive assay, Elecsys 
Troponin T (Roche Diagnostics, Indianapolis, IN), on an automated Cobas e411 analyzer 
with a lower limit of detection of 3 ng/L. The 99th percentile value for the cTnT measured 
by the new assay in a healthy subpopulation is 14 ng/L (Roche Diagnostics, data on file). 
The between-assay coefficients of variation were 2.6% and 6.9% for control materials with 
mean cTnT concentrations of 238 ng/L and 29 ng/L, respectively.
 Study Design
A total of five sub-studies (I to V) were conducted – four of them to estimate the 
components of variability i.e., laboratory, processing, short term biological and long term 
biological, and the fifth to estimate degradation over 3 years. In sub-study I examining 
laboratory variability, 30 samples (15 each from individuals with and without HF) from the 
ARIC Carotid MRI study were split into 2 aliquots, and values obtained from the paired 
assays were compared and measure of variation estimated. One participant without HF had 
cTnT below limit of detection (LOD) in split assay; thus information from 14 participants 
was available for estimation. Measurement variation estimated from these data cannot be 
attributed to variation in blood drawing, local processing, shipment procedures, laboratory 
handling and analysis, or within-subject variation over time. A schematic diagram showing 
various components of variability in the measurement of an assay is shown in supplementary 
figure 1.
In sub-study II involving 119 Carotid MRI study participants, each field center drew 
duplicate blood tubes using a single venipuncture during the same visit but were processed 
(shipping and other details) separately. These duplicate samples were sent to the central 
laboratory under a blinded quality control (QC) ID that was not distinguishable from how 
other IDs were labeled and then stored. After the laboratory had analyzed the paired samples 
the results were compared to estimate the processing variability (i.e., variability in blood 
processing, shipping, and laboratory handling and analysis) for samples above LOD in 
replicate samples (n = 87).
In sub-study III involving 60 Carotid MRI study participants, each field center was asked to 
recruit 15 volunteers to repeat the entire clinic visit within 4–8 weeks of their original visit. 
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Volunteers generally reflected the age, sex, and racial composition of the overall study [18]. 
Again, duplicate samples were submitted to the central laboratory and stored under a blinded 
QC ID. Results from the paired samples were compared to give an estimate of short term 
biologic variability when assays were above LOD at both times (n = 40). It is to be noted 
that in this and all similar studies paired samples from participants over time will also 
include variability due to laboratory and processing error too.
In sub-study IV with 161 participants, samples from Carotid MRI study visit (sub-study I 
through III) and corresponding assays from samples stored during visit 4 (about 8 years 
before) were used and measures of long term biological variability were assessed after 
excluding those with CHD, HF, or stroke during the Carotid MRI visit.
In sub-study V, stored samples from all the participants who participated in the ARIC cohort 
field center visit 4 (n = 10,870) and had cTnT above LOD (n=7,677) were used. There were 
differences in storage period since collection was spread over an average 3 years, enabling 
an estimation of degradation during frozen storage.
 Covariates
Smoking status, race, and gender, were self reported. Estimated glomerular filtration rate 
(eGFR) was calculated using the Modification of Diet in Renal Disease formula [19]. 
Prevalent coronary heart disease (CHD) was defined as either self-reported history of CHD 
at the baseline visit or an adjudicated CHD event before the fourth exam visit (for the visit 4 
analyses) or 12/31/2004, the last date of adjudication (for Carotid MRI study visit). 
Participants with hospitalizations listing the International Classification of Diseases, Ninth 
Revision (ICD-9) discharge code = 428 in any position were classified with prevalent heart 
failure.
 Statistical Methods
Descriptive statistics are presented for participants in each of the sub-studies (I through V) 
and participants of ARIC Carotid MRI study. By treating paired measurements as a random 
effect in a linear mixed effects model, we partitioned the total variance ( ) into a 
between-pair (or between-person, ) and within-pair component of variance. The within-
pair component of variance derived from within-visit reliability sub-study II, in which 
duplicate samples were obtained from participants on the same day, corresponds to an 
estimate of variation due to blood collection, processing and laboratory analysis ( ). In 
contrast, the within-pair component of variance derived from between-visit reliability sub-
study III and sub-study IV, in which duplicate samples were obtained from participants at 
two separate visits, corresponds to an estimate of the within-person (biologic) variation over 
time plus method variation ( ). The within-pair variance derived from the split-
samples after one freeze-thaw cycle (sub-study I) corresponds to the laboratory variability 
plus analyte stability. The proportion of the total variance attributable to between-person 
variability, or the reliability coefficient ( ) can be interpreted as the correlation 
between paired measurements. The following benchmarks were used for characterization of 
the adequacy of reliability [20]: slight reliability, 0–0.2; fair reliability, 0.21–0.4; moderate 
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reliability, 0.41–0.6; substantial reliability, 0.61–0.8; almost perfect reliability, 0.81–1.0. 
Based on our sample sizes of 87 and 40 for the two sub-studies, the 95% confidence interval 
assuming a moderate reliability of 0.60 will have lower limits of 0.45 and 0.38, respectively.
Coefficient of variation (CV) was derived as the standard deviation of the within-pair 
differences divided by the mean of the paired observations multiplied by 100. CV values 
greater than 10% for laboratory or processing variability were considered as a cause for 
concern.
Reference change values (RCV) were defined as that difference between two consecutive 
test results in an individual that is statistically significant in a given proportion of all similar 
persons [21]. For estimating RCV, those below limit of detection were not included. 
Reference change values (RCV) were calculated as , where Z is the 
number of standard deviates required for a stated probability under the normal curve. The 
number of specimens required to produce a precise homeostatic set point estimate is given 
as: , where D is the desired percentage closeness to the homeostatic set 
point [22]. Bland-Altman plots (sub-study III and IV) were used to assess the degree of 
disagreement (including systematic differences) and identify outliers and trends between the 
two repeat measures at 4–8 weeks apart [23].
Although our study design precluded performing cTnT assays at pre-specified time intervals 
to evaluate sample degradation at −70° C storage over time, the timing of the cohort 
examination visits in ARIC was assigned at random, resulting in a uniform distribution of 
participants by study month. Degradation in stored frozen storage was therefore examined 
by regressing analyte concentration on time since specimen collection. A roughly flat slope 
would suggest little degradation, whereas a negative slope would provide evidence of sample 
decay.
Analysis were done using SAS software version 9.2, Cary, NC.
 Results
Demographic and clinical characteristics of study participants for sub-studies I through V 
are shown in table 1. Median age at sample collection was 63 years at visit 4 (long term 
variability and degradation study) and over 70 years for sub-studies I through III using only 
Car-MRI visit data. The average prevalence of co-morbidities in sub-studies during visit 4 
and Car-MRI visit was CHD (6 to 8% vs. 15 to 18%), and heart failure (2.4 to 2.5% vs. 5.0 
to 6.0%) respectively.
Estimates of the 95th and 99th percentiles of cTnT in the ARIC visit 4 cohort (n=10,870) 
were 18 ng/L and 40 ng/L with inter-quartile range of 3 to 8 ng/L. Also, 31.6% of visit 4 
samples and 26.9 % of Car MRI samples were below detection limits.
cTnT measures after a single freeze thaw cycle (sub-study I), different processing after 
collection from a single venous stick (processing reliability, sub-study II), repeat visit within 
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4–8 weeks (sub-study III), demonstrated very high reliability with r>0.93 (table 2). 
However, reliability after 8 years duration (sub-study IV) was low, r = 0.36 (Table 2).
After removing observations below the LOD, the mean of cTnT were 24.5 ng/L in those 
with HF vs. 8.6 ng/L in those without. The CVs in paired replicate after a freeze-thaw cycle 
in those with and without HF in were 2.1% and 11.2%, respectively. There was high 
processing variability with CV of 18.3% (though reliability was high, r = 0.93).
The variability between repeated visits 4–8 weeks apart was not large (CV = 16.6%). The 
mean of the differences between these repeat visits was 0 ng/L with a range from −5 to 6 
ng/L and inter-quartile range (IQR) from - 1 ng/L to 1 ng/L. Bland-Altman plots (figure 1) 
did not support a relationship between differences in cTnT measures and the mean cTnT 
level. The RCV, calculated using repeat visits spaced approximately six weeks apart, was 
68.5%, suggesting that cTnT changes over a six week interval must be greater than 67% of 
the baseline value to be considered biologically significant (table 3). Correspondingly, for a 
six-week interval, 23 and 4 samples would be needed to identify an individuals’ cTnT (i.e. 
homeostatic set point) level within ±10% and ±25% with 95% confidence, respectively 
(Table 3).
Examination of long term (i.e. 8-year) biological variability suggests a SD of 4.3 at a mean 
value of 9 ng/L (CV = 48.4%). The mean of differences between these visits 8 years apart 
was 1.6 ng/L with range from −16 to 14 ng/L and IQR from - 4 ng/L to 1 ng/L. There was 
evidence of late degradation when stored sample collected over a period of 36 months was 
regressed on time since collection. A mean degradation of 0.36 (95% CI: 0.19 to 0.53) ng/L 
in cTnT per year was seen (figure 2). This degradation was not evident when we examined 
proportions of samples below detection limit collected during a quarter year with varying 
duration of storage since collection during visit 4 to measurement in 2009–10 
(supplementary figure 2).
 Discussion
This study comprehensively reports on various components of variability in the 
measurement of high sensitivity Troponin T and on the stability of troponin T in samples 
stored at −70 °C. The laboratory reliability of the cTnT assay was high: the reliability 
coefficient (R) was 0.99 in those with heart failure and 0.94 in those without heart failure. 
The intra-individual (biologic) variability was similarly high after 6 weeks (R=0.94), but was 
lower t after 8 years (R=0.36). After excluding those with events (CHD, HF, and stroke) 
between the repeat visits, R changed to 0.28 and CV was 54.9% (as compared to 48.4% in 
the complete sample).
In another study using the pre-commercial electrochemiluminescense assay (ECLIA; 
Elecsys 2010 analyzer, Roche Diagnositics, Germany) the limit of detection was 1 ng/L 
[14]. A significant correlation was reported between highly sensitive cTnT assay and 
traditional cTnT assay in those with detectable limit (r=0.84). The intra-assay coefficient of 
variation was 5% at 10 ng/L and 1% at 100 ng/L [14].
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In a recent study examining components of variability in 20 healthy and young volunteers 
(age range 25–56 years), very short term (0–4 hrs) and short term (0–8 weeks) intra-
individual CV were 48% and 85%, respectively [16]. The CV at short term (85%) was 
higher than that seen in the study reported here (16.6%) – possibly a function of lower mean 
value of cTnT in a study of healthy young volunteers. In our study there were no appreciable 
changes in the intra-individual CV (18.5%) after excluding those without CHD or HF or AF.
We are not aware of published studies of the stability of cTnT in stored specimens. Using an 
indirect approach this study indicates that there is little late phase degradation, however, 
degradation in the early period of storage could not be ruled out. There was no indication of 
an increase in proportion of the population below the lower limit of detection with longer 
freezer storage time (Supplementary figure 2), although the study power for detecting such a 
change is limited.
It has been reported that the use of a sensitive assay for troponin I improves the early 
diagnosis of acute myocardial infarction (AMI) and aids in risk stratification, regardless of 
the time of chest-pain onset [27] whereas cTnT did not have higher diagnostic accuracy for 
AMI [24]. In general, the use of high sensitivity troponin assays improves the information at 
the lower tail of distribution of cardiac troponin levels, which is usually left-censored and 
assumed to be either, zero or set at the lower limit of detection. As shown by several studies 
[5–12] such lower range of values when detectable helps in prognostication .Whether a 
change in such low range can help in early detection and prevention of myocardial injury 
such as in drug induced cardiomyopathy or ischemia not amounting to infarction requires 
additional study. Given the favorable measurement properties of cTnT reported here and 
elsewhere [14] the ability to detect very low levels of plasma cTnT should allow for a wider 
range of applications in the clinical context and in research.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Bland-Altman plot showing bias against the mean of cTnT measurements obtained six 
weeks and eight years apart with 95% levels of agreement (broken lines). The differences 
and means are expressed in microgram/L.
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Influence of time since collection on cTnT concentration in n=7,677 samples collected over 
1,093 days in 1996–98 and stored at −70 °C till measurement in 2009–2010 i.e. freezer time 
varying from 11 to 14 years.
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Table 3
Reference change values and number of samples needed to determine homeostatic set point for cTnT over 6 
week measurement intervals. The ARIC Carotid MRI Study, 2005–2006
RCV, % 68.5
No. samples
  (±10; CI 95%) 23
  (±25; CI 95%) 4
  (±50; CI 95%) 1
CI, confidence interval; cTnT, high sensitivity troponin T; RCV, reference change value
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